Patent settlements still rising, but potentially troublesome deals stable, says EC
This article was originally published in Scrip
Executive Summary
The number of patent settlements between originator and generic companies in Europe continued to rise in 2012, but the proportion of deals that could attract scrutiny under competition law issues has stabilized at a low level, suggesting that companies are more aware of potentially problematic practices, says the European Commission.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.